US Stock MarketDetailed Quotes

KPRX Kiora Pharmaceuticals

Watchlist
  • 3.2200
  • -0.0700-2.13%
Close Mar 18 16:00 ET
  • 3.2200
  • 0.00000.00%
Post 20:01 ET
9.66MMarket Cap3.07P/E (TTM)

About Kiora Pharmaceuticals Company

Kiora Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes KIO-301, which is designed to restore vision in patients with inherited and age-related degenerative retinal disease, KIO-101 for patients with Ocular Presentation of Rheumatoid Arthritis, KIO-201 for patients undergoing PRK surgery for corneal wound repair after refractive surgery, and KIO-102. The company was founded in 1998 and is headquartered in Encinitas, CA.

Company Profile

SymbolKPRX
Company NameKiora Pharmaceuticals
Listing DateFeb 13, 2015
Issue Price6.00
Founded1998
CEOMr. Brian M. Strem, PhD
MarketNASDAQ
Employees12
Fiscal Year Ends12-31
Address332 Encinitas Boulevard,Suite 102
CityEncinitas
ProvinceCalifornia
CountryUnited States of America
Zip Code92024
Phone1-858-224-9600

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Brian M. Strem, PhD
  • Director, President and Chief Executive Officer
  • 802.27K
  • Melissa Tosca, C.P.A.
  • Chief Financial Officer and Principal Accounting Officer
  • 387.48K
  • Eric J. Daniels
  • Chief Development Officer
  • 652.31K
  • Dr. Praveen Tyle, PhD
  • Chairman of the Board
  • 98.25K
  • Aron Shapiro
  • Director
  • 70.12K
  • Carmine Stengone
  • Independent Director
  • 24.58K
  • Lisa Walters Hoffert
  • Independent Director
  • --
  • Dr. David A. Hollander, M.D.
  • Independent Director
  • 77.62K
  • Erin Parsons
  • Independent Director
  • 84.50K

Trending Stocks

Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Discussing
Fed’s March rate decision nears: Market pivot ahead?
How will the Fed's rate decision impact short-term trends in U.S. stocks? How would you reposition your portfolio? Show More